- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
The Top 5 Biosimilars Articles for the Week of November 4
The Center for Biosimilars® recaps the top stories for the week of November 4, 2019.
Transcript
Hi, I’m Laura Joszt for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of November 4, 2019.
Number 5: The biggest cost difference in filgrastim administrations was seen in the commercially insured population after the launch of a biosimilar, according to a new study.
Number 4: The FDA has issued an establishment inspection report for Biocon’s biosimilars facility, and the company says that it plans to launch its trastuzumab biosimilar soon.
Number 3: Samsung Bioepis has entered into a new commercialization agreement with Biogen for 2 ophthalmology biosimilars.
Number 2: Effective January 1, 2020, UnitedHealthcare patients who are receiving the reference epoetin alfa will be required to switch to Pfizer’s biosimilar.
Number 1: At the end of a lengthy regulatory road for Sandoz, the FDA approved the company’s biosimilar pegfilgrastim referencing Neulasta.
Finally, our e-newsletter asked whether you think that enacting legislation to create a CMS star ratings system based on biosimilar availability would help improve biosimilar uptake.
To view results of the poll, visit us on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Biosimilar Approvals Streamlined With Advanced Statistics Amidst Differing Regulatory Requirements
February 25th 2025The FDA and European Medicines Agency (EMA) mandate high similarity between biosimilars and reference products, but their regulatory processes differ, especially with multiple reference products.
